Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion

Spero Therapeutics licensed rights (outside Greater China) to Innovent Biologics’ experimental autoimmune disease treatment in a deal valued at up to ~$1.1B. The upfront/milestone structure suggests meaningful upside for Spero contingent on development and commercialization milestones, a positive signal for its biotech pipeline execution.

Analysis

Spero Therapeutics licensed rights (outside Greater China) to Innovent Biologics’ experimental autoimmune disease treatment in a deal valued at up to ~$1.1B. The upfront/milestone structure suggests meaningful upside for Spero contingent on development and commercialization milestones, a positive signal for its biotech pipeline execution.